OssDsign (OSSD.ST) Stock Analysis & AI Equity Report
OssDsign (OSSD.ST) overview
OssDsign (OSSD.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, OssDsign reported revenue of SEK 180m and operating profit of SEK -48.4m; the year-end share price was 11.34 SEK and market capitalisation was SEK 1,253m. OssDsign is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get OssDsign's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About OssDsign
OssDsign AB is a Swedish medical device company focused on orthobiologics. It develops and markets next-generation bone graft products based on material science, including OssDsign Catalyst, an off-the-shelf nanosynthetic bone graft used in spinal fusion and other skeletal repair applications. The company has also shifted away from its former cranial implant business to concentrate on orthobiologics.
Generate the OssDsign report
OssDsign is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for OssDsign and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.